A proof of concept phase I/II pilot trial of LSD1 inhibition by tranylcypromine combined with ATRA in refractory/relapsed AML patients not eligible for intensive therapy

All-trans-retinoic acid (ATRA) is highly active in acute promyelocytic leukemia but not in other types of acute myeloid leukemia (AML). Previously, we showed that ATRA in combination with Lysine-specific demethylase 1 (LSD1) inhibition by tranylcypromine (TCP) can induce myeloid differentiation in A...

Descripción completa

Detalles Bibliográficos
Autores principales: Wass, Maxi, Göllner, Stefanie, Besenbeck, Birgit, Schlenk, Richard F., Mundmann, Petra, Göthert, Joachim R., Noppeney, Richard, Schliemann, Christoph, Mikesch, Jan-Henrik, Lenz, Georg, Dugas, Martin, Wermke, Martin, Röllig, Christoph, Bornhäuser, Martin, Serve, Hubert, Platzbecker, Uwe, Foerster, Kathrin I., Burhenne, Jürgen, Haefeli, Walter E., Müller, Lutz P., Binder, Mascha, Pabst, Caroline, Müller-Tidow, Carsten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7303943/
https://www.ncbi.nlm.nih.gov/pubmed/32561840
http://dx.doi.org/10.1038/s41375-020-0892-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7303943/
https://www.ncbi.nlm.nih.gov/pubmed/32561840
http://dx.doi.org/10.1038/s41375-020-0892-z

Ejemplares similares